| Literature DB >> 31920913 |
Jitian Guan1,2,3, Xilun Ma4, Yiqun Geng2,3,5, Dan Qi2,3, Yuanyu Shen1, Zhiwei Shen1, Yanzi Chen1, Erxi Wu2,3,6,7,8, Renhua Wu1.
Abstract
We aimed to evaluate microscale changes in the bilateral red nucleus and substantia nigra of patients with Parkinson's disease (PD) using diffusion kurtosis imaging (DKI). Twenty-six patients with PD [mean age, 62.5 ± 8.7 years; Hoehn-Yahr stage, 0-4.0; Unified Parkinson's Disease Rating Scale (UPDRS) scores, 8-43] and 15 healthy controls (mean age, 59.5 ± 9.4 years) underwent DKI of the substantia nigra and red nucleus. Imaging was performed using a General Electric (GE) Signa 3.0-T MRI system. Patients with PD were divided into two groups consisting of 12 patients with UPDRS scores ≥ 30 and 14 patients with UPDRS scores < 30. All DKI data processing operations were performed with commercial workstations (GE, ADW 4.6) using Functool software to generate color-coded and parametric maps of mean kurtosis (MK), fractional anisotropy (FA), and mean diffusivity (MD). MK values in the bilateral substantia nigra were significantly lower in patients with early- and advanced-stage PD than in controls. Moreover, MK values in the left substantia nigra were significantly lower in patients with advanced-stage PD than in those with early-stage PD. Patients with advanced-stage PD also exhibited significant decreases in MK values in the bilateral red nucleus relative to controls. No significant differences in FA or MD values were observed between the PD and control groups. There were no significant correlations between MK, FA, or MD values and UPDRS scores. Our findings suggest that decreased MK values in the substantia nigra may aid in determining the severity of PD and help provide early diagnoses.Entities:
Keywords: Parkinson's disease; diffusion kurtosis imaging; magnetic resonance imaging; red nucleus; substantia nigra
Year: 2019 PMID: 31920913 PMCID: PMC6914993 DOI: 10.3389/fneur.2019.01285
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Mean kurtosis values for the bilateral substantia nigra in the Parkinson's disease and control groups. CTL, control; MKLSN, mean kurtosis of the left substantia nigra; MKRSN, mean kurtosis of the right substantia nigra; PD, Parkinson's disease. *p < 0.05.
Diffusion kurtosis imaging values in the bilateral red nucleus and substantia nigra in the Parkinson's disease and control groups.
| MK | 1.204 ± 0.061 | 1.500 ± 0.072 | 0.022 |
| MD | 0.547 ± 0.125 | 0.551 ± 0.119 | 0.934 |
| FA | 0.454 ± 0.134 | 0.497 ± 0.109 | 0.296 |
| MK | 1.181 ± 0.052 | 1.486 ± 0.069 | 0.023 |
| MD | 0.520 ± 0.116 | 0.538 ± 0.110 | 0.617 |
| FA | 0.477 ± 0.087 | 0.464 ± 0.144 | 0.728 |
| MK | 1.336 ± 0.247 | 1.451 ± 0.184 | 0.127 |
| MD | 0.517 ± 0.114 | 0.551 ± 0.159 | 0.440 |
| FA | 0.447 ± 0.112 | 0.511 ± 0.145 | 0.125 |
| MK | 1.407 ± 0.251 | 1.525 ± 0.188 | 0.119 |
| MD | 0.500 ± 0.137 | 0.521 ± 0.121 | 0.622 |
| FA | 0.450 ± 0.112 | 0.501 ± 0.159 | 0.241 |
CTL, control; DKI, diffusion kurtosis imaging; FA, fractional anisotropy; MD, mean diffusivity; MK, mean kurtosis; PD, Parkinson's disease; RN, red nuclei; SN, substantia nigra; SD, standard deviation.
p < 0.05, PD vs. CTL.
Figure 2Diffusion kurtosis imaging values in the substantia nigra for the control, early-stage Parkinson's disease, and advanced-stage Parkinson's disease groups. ASPD, advanced-stage Parkinson's disease; CTL, control; ESPD, early-stage Parkinson's disease; FALSN, fractional anisotropy of the left substantia nigra; FARSN, fractional anisotropy of the right substantia nigra; MDLSN, mean diffusivity of the left substantia nigra; MDRSN, mean diffusivity of the right substantia nigra; MKLSN, mean kurtosis of the left substantia nigra; MKRSN, mean kurtosis of the right substantia nigra. **p < 0.01, ASPD vs. CTL; *p < 0.05, early-stage PD vs. CTL or advanced-stage PD vs. CTL or advanced-stage PD vs. early-stage PD.
Diffusion kurtosis imaging values in the bilateral red nucleus and substantia nigra in the control, early-stage Parkinson's disease, and advanced-stage Parkinson's disease groups.
| MK | 1.500 ± 0.072 | 1.276 ± 0.042 | 1.021 ± 0.053 |
| MD | 0.551 ± 0.119 | 0.552 ± 0.115 | 0.542 ± 0.140 |
| FA | 0.497 ± 0.109 | 0.445 ± 0.118 | 0.465 ± 0.155 |
| MK | 1.486 ± 0.069 | 1.225 ± 0.074 | 1.073 ± 0.065 |
| MD | 0.538 ± 0.110 | 0.538 ± 0.103 | 0.499 ± 0.131 |
| FA | 0.464 ± 0.144 | 0.476 ± 0.082 | 0.478 ± 0.097 |
| MK | 1.511 ± 0.084 | 1.391 ± 0.075 | 1.232 ± 0.096 |
| MD | 0.551 ± 0.159 | 0.448 ± 0.112 | 0.453 ± 0.117 |
| FA | 0.511 ± 0.145 | 0.434 ± 0.101 | 0.463 ± 0.127 |
| MK | 1.525 ± 0.096 | 1.419 ± 0.093 | 1.271 ± 0.085 |
| MD | 0.521 ± 0.121 | 0.512 ± 0.145 | 0.485 ± 0.133 |
| FA | 0.501 ± 0.159 | 0.448 ± 0.112 | 0.453 ± 0.117 |
CTL, control; DKI, diffusion kurtosis imaging; FA, fractional anisotropy; MD, mean diffusivity; MK, mean kurtosis; PD, Parkinson's disease; RN, red nuclei; SN, substantia nigra; SD, standard deviation.
p < 0.05, early-stage PD vs. CTL or advanced-stage PD vs. CT or advanced-stage PD vs. early-stage PD.
p < 0.01, advanced-stage PD vs. CTL.
Figure 3Diffusion kurtosis imaging values in the red nucleus for the control, early-stage Parkinson's disease, and advanced-stage Parkinson's disease groups. ASPD, advanced-stage Parkinson's disease; CTL, control; ESPD, early-stage Parkinson's disease; MDLRN, mean diffusivity of the left red nucleus; FALRN, fractional anisotropy of the left red nucleus; FARRN, fractional anisotropy of the right red nucleus; MDRRN, mean diffusivity of the right red nucleus; MKLRN, mean kurtosis of the left red nucleus; MKRRN, mean kurtosis of the right red nucleus. *p < 0.05, ESPD vs. CTL or ASPD vs. CTL or ASPD vs. ESPD.
Figure 4Diffusional kurtosis images of volumes of interest in the bilateral red nucleus and substantia nigra (A–D). (A) Volumes of interest in the bilateral red nucleus and substantia nigra. We obtained data from maps of the (B) mean diffusivity, (C) fractional anisotropy, and (D) mean kurtosis.